Saturday, July 22, 2023 10:38:26 AM
Tried to refresh my memory on Lux G3 and noticed something weird. Look at slide 31 of EHA presentation. It shows time course of Lux plasma concentration in cycle 1 at different drug doses. First, Look at 900 mg dose curve. Lux level reaches almost 1 uM on day 15 and then it drops to ~0.15 uM at the end of cycle. Second, how to explain a sudden plunge in plasma Lux on day 15 with 750 mg G1 and 50 mg G3? And why so many measurements on day 15? Third, why to compare 50 mg G3 with 900 mg G1, a worst PK dose, and not with 600 mg G1? Fourth, why do you see plasma Lux decline with 50 mg G3 from day 8 to day 15 and day 22? Where is data for day 29?
Recent APTOF News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/13/2026 09:15:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/13/2026 09:15:17 PM
- Aptose Reports First Quarter 2026 Results • GlobeNewswire Inc. • 05/13/2026 09:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/30/2026 11:35:19 AM
- Aptose Biosciences Announces Update on Anticipated Timing of Closing of the Plan of Arrangement with Hanmi Pharmaceutical • GlobeNewswire Inc. • 04/30/2026 11:30:00 AM
- Form SC 13E3/A - Going private transaction by certain issuers: [Amend] • Edgar (US Regulatory) • 04/01/2026 08:14:53 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/31/2026 09:29:22 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/31/2026 09:23:27 PM
- Aptose Biosciences Announces Results of Special Shareholders Meeting; Announces Receipt of Final Court Approval of Plan of Arrangement; Reports Year End 2025 Results and Corporate Highlights • GlobeNewswire Inc. • 03/31/2026 09:22:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/31/2026 08:59:27 PM
- Form RW - Registration Withdrawal Request • Edgar (US Regulatory) • 03/23/2026 09:15:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/23/2026 09:02:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/23/2026 11:30:11 AM
- Leading Independent Proxy Advisory Firm Glass Lewis Endorses Aptose Plan of Arrangement • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/19/2026 11:40:10 AM
- Leading Independent Proxy Advisory Firm ISS Recommends Aptose Biosciences Shareholders Vote “FOR” Proposed Plan of Arrangement with Hanmi Pharmaceutical • GlobeNewswire Inc. • 03/19/2026 11:30:00 AM
- Aptose Biosciences Announces Amendment to Arrangement Agreement and Details of Postponed Special Meeting of Shareholders • GlobeNewswire Inc. • 02/24/2026 12:00:00 PM
- Form SC 13E3/A - Going private transaction by certain issuers: [Amend] • Edgar (US Regulatory) • 02/17/2026 11:13:46 AM
- Form PRER14A - Preliminary Proxy Soliciting materials • Edgar (US Regulatory) • 02/17/2026 11:06:40 AM
- Form SC 13E3/A - Going private transaction by certain issuers: [Amend] • Edgar (US Regulatory) • 02/09/2026 11:15:56 AM
- Form PRER14A - Preliminary Proxy Soliciting materials • Edgar (US Regulatory) • 02/09/2026 11:06:31 AM
- Form SC 13E3 - Going private transaction by certain issuers • Edgar (US Regulatory) • 01/15/2026 02:26:21 AM
- Form PRER14A - Preliminary Proxy Soliciting materials • Edgar (US Regulatory) • 01/15/2026 02:23:33 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/19/2025 10:16:17 PM
- Aptose Biosciences Announces Rescheduling of Special Meeting of Shareholders to Approve the Acquisition by Hanmi Pending Final Clearance from SEC • GlobeNewswire Inc. • 12/19/2025 10:05:31 PM
